42 patents
Page 2 of 3
Utility
Use of Highly Potent Multimeric E-selectin Antagonists for Treating Sickle Cell Disease
18 Aug 22
Methods for the treatment of sickle cell disease or complications associated therewith, including, for example, vaso-occlusive crisis, by the use of at least one E-selectin inhibitor and compositions comprising the same are disclosed.
John L. MAGNANI, William E. FOGLER
Filed: 30 Jul 20
Utility
Multimeric Pan-selectin Antagonists
14 Jul 22
John L. MAGNANI, John M. PETERSON
Filed: 21 Apr 20
Utility
Galactopyranosyl-cyclohexyl Derivatives As E-selectin Antagonists
9 Jun 22
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed.
John L. MAGNANI, John M. PETERSON, Arun K. SARKAR, Yusuf U. VOHRA, Myung-Gi BAEK
Filed: 9 Nov 21
Utility
E-selectin antagonist compounds, compositions, and methods of use
17 May 22
Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand.
John L. Magnani, Arun K. Sarkar, Myung-Gi Baek, Frank E. Anderson, III, Yanhong Li
Filed: 17 Aug 20
Utility
Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
5 Apr 22
New methods for treating and/or preventing cardiovascular disease including, for example, myocardial infarction and atherosclerosis, by the use of at least one E-selectin inhibitor and compositions comprising the same are disclosed.
John L Magnani, Matthias P Nahrendorf
Filed: 1 Mar 17
Utility
Heterobifunctional Inhibitors of E-selectin and GALECTIN-3
24 Mar 22
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin, galectin-3, or E-selectin and galectin-3 to ligands are disclosed.
John L. MAGNANI, John M. PETERSON, Arun K. SARKAR, Yusufbhai U. VOHRA, Indranath GHOSH, Jason NOGUEIRA
Filed: 26 Dec 19
Utility
GALECTIN-3 Inhibiting C-glycosides
10 Mar 22
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of galectin-3 to ligands are disclosed.
John L. MAGNANI, John M. PETERSON, Arun K. SARKAR, Yusufbhai U. VOHRA, Indranath GHOSH, Jason NOGUEIRA
Filed: 26 Dec 19
Utility
Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists
14 Dec 21
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed.
John L Magnani, John M Peterson, Arun K Sarkar, Yusuf U Vohra, Myung-Gi Baek
Filed: 12 Mar 18
Utility
Highly Potent Multimeric E-selectin Antagonists
21 Oct 21
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed.
John L. MAGNANI, John M. PETERSON, Myung-Gi BAEK
Filed: 15 Jun 21
Utility
Highly potent multimeric e-selectin antagonists
27 Jul 21
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed.
John L. Magnani, John M. Peterson, Myung-Gi Baek
Filed: 6 Oct 17
Utility
Glycomimetic inhibitors of PA-IL and PA-IIL lectins
29 Jun 21
Compounds, compositions, and methods for the diagnosis and/or treatment of medical conditions involving infections with and colonization by Pseudomonas bacteria including, for example, Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis are described.
John L Magnani, Arun K. Sarkar
Filed: 18 Jan 17
Utility
Methods of Mobilizing Marrow Infiltrating Lymphocytes and Uses Thereof
17 Jun 21
Methods are disclosed for the mobilization of marrow infiltrating cells (MILs) using E-selectin antagonists for the treatment of disorders such as cancer.
John L. MAGNANI, William FOGLER
Filed: 29 Nov 18
Utility
Methods for Treating Acute Myeloid Leukemia and Related Conditions
11 Mar 21
Methods for treating or inhibiting cancer and/or one or more related conditions by administering to a subject in need thereof an effective amount of a compound of Formula (I), a prodrug thereof, or a pharmaceutically acceptable salt of any of the foregoing.
Helen M. THACKRAY, Henry H. FLANNER, Curt D. WOLFGANG
Filed: 4 Mar 19
Utility
E-selectin Antagonist Compounds, Compositions, and Methods of Use
21 Jan 21
Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand.
John L. MAGNANI, Arun K. SARKAR, Myung-Gi BAEK, Frank E. ANDERSON, III, Yanhong LI
Filed: 17 Aug 20
Utility
Heterobifunctional Inhibitors of E-selectin and GALECTIN-3
23 Dec 20
John L. MAGNANI, John M. PETERSON, Arun K. SARKAR, Yusufbhai U. VOHRA, Hong-Woon YANG
Filed: 27 Dec 18
Utility
Haloalkyl Fucose-containing Selectin Antagonists
7 Oct 20
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed.
Beat ERNST, Norbert VARGA, Martin SMIESKO, Beatrice WAGNER, John M. PETERSON, John L. MAGNANI
Filed: 21 May 17
Utility
E-selectin antagonist compounds, compositions, and methods of use
7 Sep 20
Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand.
John L. Magnani, Arun K. Sarkar, Myung-Gi Baek, Frank E. Anderson, III, Yanhong Li
Filed: 19 Nov 19
Utility
CorrectedHeterobifunctional Pan-Selectin Antagonists Having a Triazole Linker
3 Jun 20
Beat ERNST, Beatrice WAGNER
Filed: 29 Nov 16
Utility
E-selectin Antagonist Compounds, Compositions, and Methods of Use
20 May 20
Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand.
John L. MAGNANI, Arun K. SARKAR, Myung-Gi BAEK, Frank E. ANDERSON, III, Yanhong LI
Filed: 19 Nov 19
Utility
Galactopyranosyl-cyclohexyl Derivatives As E-selectin Antagonists
29 Apr 20
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed.
John L MAGNANI, John M PETERSON, Arun K SARKAR, Yusufbhai U VOHRA, Myung-Gi BAEK
Filed: 11 Mar 18